This provides the rationale to investigate CDH1 promoter/enhancer methylation in the gastric tissue of patients with suspected genetic predisposition to GC, since it could be an early event of the carcinogenesis process in HDGC CDH1-negative patients. This evidence concerns the gene DSG2 and gastric cancer.